Tevogen Bio Statistics
Share Statistics
Tevogen Bio has 183.89M
shares outstanding. The number of shares has increased by 4.75%
in one year.
| Shares Outstanding | 183.89M |
| Shares Change (YoY) | 4.75% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.36% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 42,416 |
| FTD / Avg. Volume | 4.81% |
Short Selling Information
The latest short interest is 3.22M, so 1.75% of the outstanding
shares have been sold short.
| Short Interest | 3.22M |
| Short % of Shares Out | 1.75% |
| Short % of Float | 6.54% |
| Short Ratio (days to cover) | 1.3 |
Valuation Ratios
The PE ratio is -11.01 and the forward
PE ratio is -5.35.
Tevogen Bio's PEG ratio is
0.
| PE Ratio | -11.01 |
| Forward PE | -5.35 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | -22.64 |
| P/FCF Ratio | -12.59 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Tevogen Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.26,
with a Debt / Equity ratio of -0.43.
| Current Ratio | 0.26 |
| Quick Ratio | 0.26 |
| Debt / Equity | -0.43 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.24 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-762,632.22 |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 59.76% in the
last 52 weeks. The beta is -0.8, so Tevogen Bio's
price volatility has been lower than the market average.
| Beta | -0.8 |
| 52-Week Price Change | 59.76% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 67.89 |
| Average Volume (20 Days) | 882,538 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -53.56M |
| Net Income | -13.73M |
| EBITDA | -53.56M |
| EBIT | -13.91M |
| Earnings Per Share (EPS) | -0.09 |
Full Income StatementBalance Sheet
The company has 1.28M in cash and 2.89M in
debt, giving a net cash position of -1.6M.
| Cash & Cash Equivalents | 1.28M |
| Total Debt | 2.89M |
| Net Cash | -1.6M |
| Retained Earnings | -113.39M |
| Total Assets | 4.07M |
| Working Capital | -5.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12M
and capital expenditures 0, giving a free cash flow of -12M.
| Operating Cash Flow | -12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12M |
| FCF Per Share | -0.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
